H.C. Wainwright raised the firm’s price target on Nyxoah to $18 from $15 and keeps a Buy rating on the shares. The analyst believes Genio could be superior to the Inspire therapy due to its ease of use, and expects the Phase 3 data to be inline with Inspire.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NYXH:
- Nyxoah to Release Fourth Quarter and Financial Year 2023 Financial Results on March 5, 2024
- Nyxoah price target raised to $14 from $10 at Cantor Fitzgerald
- Cantor Fitzgerald medtech analyst to hold an analyst/indusry conference call
- Nyxoah price target raised to $15 from $10 at Piper Sandler
- Nyxoah Stock (NASDAQ:NYXH): Don’t You Dare Sleep on This Little Runner
